Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Folegatti, Pedro M, Jenkin, Daniel, Morris, Susan, Gilbert, Sarah, Kim, Denny, Robertson, James S., Smith, Emily R., Martin, Emalee, Gurwith, Marc, Chen, Robert T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194875/
https://www.ncbi.nlm.nih.gov/pubmed/35715352
http://dx.doi.org/10.1016/j.vaccine.2022.06.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194875/
https://www.ncbi.nlm.nih.gov/pubmed/35715352
http://dx.doi.org/10.1016/j.vaccine.2022.06.008

Ejemplares similares